Live Breaking News & Updates on திரவம் தக்கவைத்தல்
Stay updated with breaking news from திரவம் தக்கவைத்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The liver is one of the body's most crucial organs, responsible for detoxifying the blood, metabolizing macronutrients, and producing chemicals that enable essential bodily processes. And during this pandemic, many of us are not treating it properly: "Although national figures are not available, admissions for alcoholic liver disease at Keck Hospital of the University of Southern California were up 30% in 2020 compared with 2019, said Dr. Brian Lee, a transplant hepatologist who treats the condition in alcoholics," reports Kaiser Health News. “There’s been a tremendous influx,” Dr. Haripriya Maddur, a hepatologist at Northwestern Medicine, told the website. Read on to see the #1 danger sign—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had Coronavirus.The #1 Danger Sign Your Liver Is in Trouble is Fluid RetentionIf your liver isn't functioning properly, it can cause serious, even ....
Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA ® and ZYTIGA ® plus prednisone (control arm). 1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST). ....
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results News provided by Share this article Share this article RARITAN, N.J., Feb. 2, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA ® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. ....